Goji Berries and Energy Expenditure
2017년 1월 31일 업데이트: Maastricht University Medical Center
The Effect of a Single Dose of Lycium Barbarum on Postprandial Energy Expenditure in Healthy Overweight Men
Effects of foods or food substances on energy expenditure are of particular interest, because of the increasing prevalence of obesity and its consequent metabolic diseases like type II diabetes and fatty liver disease, all risk factors for the development of cardiovascular diseases (CVDs).
Recently, the Goji berry (Lycium Barbarum, wolfberry) was introduced into the Western diet.
L. Barbarum originates from Asia, where it is used to improve the health of several organs.
Although L. Barbarum is promoted as a super food with many beneficial effects, consistent scientific evidence for these effects is lacking.
In one study, it was found that short-term intake of L. Barbarum polysaccharides - equal to 150 g of fresh berries - increased postprandial oxygen consumption.
This indicates that L. Barbarum might exert beneficial effects on energy expenditure.
Furthermore, long-term intervention trials have shown beneficial effects of L. Barbarum on lipid and glucose metabolism in mice and type II diabetic patients and on inflammatory status in healthy elderly.
Altogether, L. Barbarum has the potential to be used as a functional food to increase metabolic health, but detailed information on the postprandial effects of L. Barbarum is missing.
We therefore propose this double-blinded, randomized, placebo controlled intervention trial to investigate the effect of a single dose of L. Barbarum on postprandial energy expenditure substrate oxidation, metabolic flexibility, lipid and glucose metabolism and inflammatory markers.
연구 개요
상세 설명
Objectives:
The primary objective of this study is to investigate the effect of a single dose of L. Barbarum on postprandial energy expenditure. Secondary objectives are to investigate the effect of a single dose of L. Barbarum on postprandial lipid and carbohydrate oxidation and metabolic flexibility, on postprandial lipid and glucose metabolism and on inflammatory markers.
Study design:
This is a double blind, randomized, placebo-controlled intervention trial with two test days separated by a washout period of at least 1 week.
Study population:
The study population will consist of 20 apparently healthy overweight (BMI between 25 and 30 kg/m2) men aged 18-65 years.
Intervention:
All subjects will receive a mixed meal including 25 grams of dried L. Barbarum as the intervention product and a matched mixed meal without L. Barbarum as the placebo product. The meals will be matched for energy content and macronutrient composition.
연구 유형
중재적
등록 (실제)
18
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Limburg
-
Maastricht, Limburg, 네덜란드, 6229 ER
- Maastricht University Medical Center
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
예
연구 대상 성별
남성
설명
Inclusion Criteria:
- Male gender
- BMI between 25 and 30 kg/m2
- Non-smoking
- Normal fasting triacylglycerol levels (<2.2 mmol/L)
- No hyperglycaemia or hypercholesterolemia (fasting glucose < 7.0 mmol/L and total cholesterol < 8.0 mmol/L)
- Willing to comply to the study protocol during the study
- Agreeing to be informed about medically relevant personal test-results
Exclusion Criteria:
- Use of anticoagulant medication
- Unstable body weight (weight gain or loss >3 kg in the past 3 months)
- Indications of treatment according to the Standard for Cardiovascular Risk Management from the Dutch General Practitioners community
- Any medical condition that might interfere with study measurements, judged by the principal investigator, including cardiovascular disease or events (e.g. acute myocardial infarction or cerebra-vascular accident), diabetes or hypercholesterolemia
- Use of any kind of medication or medically prescribed diet, which can interfere with the study (judged by the principal investigator). The use of paracetamol is allowed
- Use of oral antibiotics (with the exception of topical antibiotics) in 40 days or less prior to the start of the study
- Use of food supplements or plant-sterol/stanol-enriched foods or supplements in the three weeks prior to the screening and/or during the study
- Not willing to abstain from L. Barbarum consumption thee weeks before the start and during the trial
- Severe medical conditions that might interfere with the study, such as epilepsy, asthma, chronic obstructive pulmonary disease and rheumatoid arthritis
- Consumption of > 14 alcohol consumptions a week
- Reported intense sporting activities > 10 hours a week
- Abuse of drugs
- Participation in any other biomedical trial one month prior to the screening visit
- Having donated > 150 ml blood within 1 month prior to the screening visit, planning to donate blood during the study or within one month after finishing the study
- Impossible or difficult to puncture as evidenced during the screening visit
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Lycium Barbarum mixed meal
Subjects will receive a high-fat mixed meal containing Lycium Barbarum once.
|
This mixed meal contains 25 grams of dried Lycium Barbarum (Goji berry, Wolfberry)
|
|
활성 비교기: Control mixed meal
Subjects will receive a high-fat mixed meal without Lycium Barbarum as a control.
|
This mixed meal does not contain Lycium Barbarum, but is matched for energy and macronutrient content
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from baseline energy expenditure
기간: Measured as the incremental area under the curve (iAUC) from 0 minutes to 140 minutes after meal intake
|
Energy expenditure will be measured using indirect calorimetry (ventilated hood system).
This system measures oxygen consumption (VO2) and carbon dioxide production (VCO2) to calculate the energy expenditure (kJ/min)
|
Measured as the incremental area under the curve (iAUC) from 0 minutes to 140 minutes after meal intake
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from baseline energy expenditure
기간: Measured as the incremental area under the curve (iAUC) from 160 minutes to 200 minutes and from 220 minutes to 260 minutes after meal intake
|
Energy expenditure will be measured using indirect calorimetry (ventilated hood system).
This system measures VO2 and VCO2 to calculate the energy expenditure (kJ/min).
|
Measured as the incremental area under the curve (iAUC) from 160 minutes to 200 minutes and from 220 minutes to 260 minutes after meal intake
|
|
Postprandial lipid and glucose oxidation
기간: At baseline (T0, fasting) and between 0 minutes and 140 minutes, between 160 minutes and 200 minutes and between 220 minutes and 260 minutes after meal consumption
|
Lipid and glucose oxidation will be calculated from indirect calorimetry data (VO2 and VCO2).
|
At baseline (T0, fasting) and between 0 minutes and 140 minutes, between 160 minutes and 200 minutes and between 220 minutes and 260 minutes after meal consumption
|
|
Metabolic flexibility
기간: At 60, 120, 180 and 240 minutes after meal intake
|
Metabolic flexibility will be derived from indirect calorimetry as the difference in respiratory quotient (RQ) between fasting and postprandial conditions.
|
At 60, 120, 180 and 240 minutes after meal intake
|
|
Markers for lipid metabolism
기간: At baseline (T0) and at regular intervals up to 240 minutes after meal consumption
|
Several markers for lipid metabolism will be measured in blood samples.
|
At baseline (T0) and at regular intervals up to 240 minutes after meal consumption
|
|
Markers for glucose metabolism
기간: At baseline (T0) and at regular intervals up to 240 minutes after meal consumption
|
Several markers for glucose metabolism will be measured in blood samples.
|
At baseline (T0) and at regular intervals up to 240 minutes after meal consumption
|
|
Inflammatory status
기간: At baseline (T0) and at 60, 120, 180 and 240 minutes after meal consumption
|
Several markers for inflammatory status will be measured in blood samples and in vitro conditions
|
At baseline (T0) and at 60, 120, 180 and 240 minutes after meal consumption
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2016년 4월 1일
기본 완료 (실제)
2016년 12월 1일
연구 완료 (실제)
2016년 12월 1일
연구 등록 날짜
최초 제출
2016년 4월 18일
QC 기준을 충족하는 최초 제출
2016년 5월 18일
처음 게시됨 (추정)
2016년 5월 23일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2017년 2월 1일
QC 기준을 충족하는 마지막 업데이트 제출
2017년 1월 31일
마지막으로 확인됨
2016년 4월 1일
추가 정보
이 연구와 관련된 용어
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .